Objective To investigate the effect the impact of plasma phosphorus fatty acid (LPA), homocysteine ( Hcy) , P-selectin in breviscapini treatment of deep venous thrombosis .Methods One hundred and twenty cases of patients with DVT were divided into observation groups ( n =60 ) and control group ( n =60 ) from June 2015 to June 2016 .Two groups were arranged with absolute bed rest , limb elevation.The control group were treated with subcutaneous heparin 100 U/kg, 2 times a day, 7 days of treatment to oral warfarin, according to international normalized ratio (INR) adjusted warfarin. Observation group were treated with intravenous Dengzhanhua 40 ml+5%glucose 250 ml, sustained 14 days of treatment to oral warfarin, adjusted according to INR warfarin .The clinical results and complications of two groups were compared .The re-canalization rate, hemorheology and the levels of plasma LPA , Hcy, P-selectin were observed before and after treatment .Re-sults The observation group at 7 d and 14 d after femoral vein , popliteal vein , posterior tibial vein thrombosis recanalization rate was significantly higher than the control group (χ2 =7.500,χ2 =5.566,χ2 =4.444,χ2 =8.086,χ2 =6.171,χ2 =8.107, P <0.05);the observation group of plasma activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT) were better than the control group ( F =242.52, F =232.69, F =202.69, P <0.05);plasma LPA, Hcy and P-selectin significantly decreased compared to the control group ( F =245.36, F =315.22, F =342.66, P <0.05).The complication rate was lower than the control group (χ2 =5.926, P =0.015).Conclusion Breviscapine injection can im-prove the recanalization rate of thrombosis in patients with DVT , improve the coagulation indexes of patients , reduce the plas-ma LPA, Hcy and P-selectin is safe and effective , worthy of clinical application .%目的：观察灯盏花素注射液对下肢深静脉血栓（ DVT）患者临床疗效及血浆血磷脂酸（ LPA）、同型半胱氨酸（ Hcy）、P-选择素水平的影响。方法2015年6月—2016年6月四川省绵阳市中心医院血管外科收治DVT患者120例，根据随机数字表法将患者分为观察组（ n ＝60）及对照组（ n ＝60），2组绝对卧床休息、患肢抬高、制动。对照组患者皮下注射肝素钠100 U／kg，每天2次，治疗7 d后改为口服华法林，根据国际标准化比值（ INR）调整华法林。观察组静脉滴注灯盏花注射液40 ml ＋5％葡萄糖250 ml，持续治疗14 d后改为口服华法林，根据INR调整华法林。分别于治疗前及治疗后观察2组血栓再通率、凝血指标及血浆LPA、Hcy及P-选择素水平的变化，并观察并发症情况。结果观察组治疗7 d、14 d后股静脉、腘静脉、胫后静脉血栓再通率显著高于对照组（χ2＝7崓．500、5．566、4．444，8．086、6．171、8．107， P ＜0．05）；观察组血浆活化部分凝血活酶时间（APTT）、凝血酶原时间（PT）、凝血酶时间（TT）较对照组明显改善（ F ＝242．52、232．69、202．69， P ＜0．05）；血浆LPA、Hcy及P-选择素较对照组显著下降（F ＝245．36、315．22、342．66， P ＜0．05）；并发症发生率低于对照组（χ2＝5．926， P ＝0．015）。结论灯盏花素注射液可提高DVT患者血栓再通率，改善患者凝血指标，降低患者血浆LPA、Hcy及P-选择素水平，安全有效，值得临床推广应用。
展开▼
